Back to Search
Start Over
27O First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target
- Source :
- ESMO Open. 8:100993
- Publication Year :
- 2023
- Publisher :
- Elsevier BV, 2023.
- Subjects :
- Cancer Research
Oncology
Subjects
Details
- ISSN :
- 20597029
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- ESMO Open
- Accession number :
- edsair.doi...........4af55b37a10160a95c236366ab5037ab
- Full Text :
- https://doi.org/10.1016/j.esmoop.2023.100993